BioCentury
ARTICLE | Company News

Spectral, Elan end assay deal

July 18, 2003 7:00 AM UTC

Spectral Diagnostics (TSE:SDI) and ELN ended their 1998 deal to develop and commercialize sepsis assays, including SDI's Endotoxin Activity Assay (EAA), which is approved to identify patients at risk ...